89bio (ETNB) Osake Kurssi

89Bio Inc is primarily active in the biotechnology industry. This innovative company focuses on developing and commercializing transformative therapies for various diseases. With its dedication to scientific advancement and breakthrough research, 89Bio Inc is a key player in the biotech sector. Through its cutting-edge technologies and collaborative partnerships, this company aims to make significant contributions to improving global healthcare. As an emerging leader in the field, 89Bio Inc continues to push boundaries and create novel solutions that have the potential to revolutionize medical treatments and positively impact patient lives.

The main competitors of 89Bio Inc in the market include prominent biopharmaceutical companies such as Amgen Inc., Gilead Sciences Inc., and Novartis AG. These industry leaders provide a range of innovative therapies, competing in various therapeutic areas where 89Bio Inc is also active. As the market continuously evolves, the competition between these companies intensifies, driving advancements and ensuring patients have access to diverse treatment options. Despite the competitive landscape, 89Bio Inc strives to differentiate itself through its unique pipeline, cutting-edge research, and commitment to developing novel therapies for patients in need.

89Bio Inc is a biopharmaceutical company that focuses on developing innovative therapies for liver and metabolic disorders. Founded in [year], 89Bio Inc has quickly emerged as a leading player in the healthcare industry. The company's extensive research and development efforts have resulted in breakthrough treatments that aim to address unmet medical needs. With a strong commitment to improving patient outcomes, 89Bio Inc has garnered recognition for its dedication to scientific excellence. This dedication, coupled with a team of experienced professionals, positions 89Bio Inc as a promising contender in the biopharmaceutical market.

89Bio Inc has achieved several significant milestones since its inception. The company successfully completed its Initial Public Offering (IPO) in August 2019, raising substantial funds to support its operations and future growth strategies. Additionally, 89Bio Inc reached an important milestone in its clinical development program with the initiation of Phase 2 clinical trials for its lead product candidate, BIO89-100. This novel therapy aims to address liver and metabolic disorders, providing a potential breakthrough in patient care. Through these accomplishments, 89Bio Inc has demonstrated its commitment to advancing innovative solutions in the healthcare sector.

89Bio Inc is primarily present in the United States.

89Bio Inc represents a strong commitment to innovation, patient-centricity, and scientific excellence. The company strives to develop transformative therapies and improve the lives of patients facing severe liver and cardio-metabolic diseases. Guided by a patient-first approach, 89Bio focuses on addressing unmet medical needs and providing novel treatment solutions. Through extensive research and collaboration, the company aims to deliver differentiated therapies that have the potential to achieve better clinical outcomes and enhance patients' quality of life. 89Bio Inc's corporate philosophy centers around a culture of integrity, accountability, and continuous learning, driving its mission to make a positive impact in the healthcare industry.

Analyytikot asettavat tällä hetkellä 89bio-osakkeelle keskimääräisen tavoitehinnan 29,52 USD (mediaani: 29,07 USD), mikä merkitsee +98,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.

89bio Analyytikkojen kursstavoitteet 2026

11 analyytikkoa arvioi tällä hetkellä 89bio-osaketta: 8 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat 89bio-yhtiöltä 3,57 M USD liikevaihtoa ja −2,94 USD osakekohtaista tulosta.

89bio Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla 89bio-osake noteerataan hintaan 13,29 EUR (14,84 USD).

89bio-osake (ETNB) on listattuna 1 pörssissä, muun muassa: NASDAQ (ETNB).

89Bio Inc is a leading biopharmaceutical company focused on the development of therapeutics for metabolic and liver diseases. The company's business model is based on identifying new target structures and developing novel biological drugs capable of addressing these targets. The company is divided into several divisions: research and development, production, sales, and marketing. The research department collaborates closely with leading scientists and biotechnology companies to gain new insights into the underlying biological processes of metabolic and liver diseases. Based on these insights, new target structures are identified, which are then used for the development of novel therapeutic agents. 89Bio's production area has state-of-the-art facilities for the manufacture of biological drugs. High-quality biological molecules are produced here for preclinical and clinical development, as well as for the marketing and trading of products. The production unit is equipped with the latest technologies and automated production lines to ensure the highest quality and efficiency. Marketing and sales activities are carried out by experienced sales professionals who work closely with doctors, medical institutions, and patient organizations. The team works to raise awareness of the company's novel therapeutic approaches and bring the products to market. This includes training for medical professionals as well as intensive patient education. The company's flagship product is BIO89-100, a novel drug for the treatment of non-alcoholic fatty liver disease. Currently, there are no approved therapeutic agents for this condition. BIO89-100 has the potential to revolutionize the standard therapy for fatty liver diseases. The company is currently conducting clinical trials to determine the efficacy and safety of the drug. Furthermore, 89Bio is developing other robust pipeline candidates that rely on innovative biological approaches to improve the treatment of liver diseases, metabolic disorders, and other conditions. Early results suggest that these drug candidates have the potential to target important goals in these areas. Overall, 89Bio aims to meet significant medical needs and improve the quality of life for patients with metabolic and liver diseases. Through its close collaboration with leading scientists and biotechnology companies, as well as its focus on innovative biological approaches, the company has the potential to become one of the leading biopharmaceutical companies in this field.

odotettu liikevaihto 89bio on 3,57 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto 89bio on −340,89 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

89bio:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,05. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan 89bio-osakkeen arvostusta.

89bio:n hinta-myynti-suhde (P/S) on tällä hetkellä 481,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii 89bio-osakkeen arvostuskennuslukuna.

89bio:n Eulpool-laatuscore on 3/10.

89bio:n ISIN on US2825591033. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

89bio:n WKN on A2PUP8. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

89bio:n ticker on ETNB. Tämä pörssinoteeraus käytetään 89bio-osakkeiden kauppaan pörssissä.